Xigris meeting rescheduled
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee will consider Lilly's Xigris (drotrecogin alfa) BLA on Oct. 16 at the Hilton in Gaithersburg, Md. starting at 8:30 a.m. The original Sept. 12 meeting was rescheduled following the terrorist attacks on Washington, D.C. and New York City (1"The Pink Sheet" Sept. 17, pp. 10 & 212)
You may also be interested in...
Ochsner Clinic Xigris Budget Projected At $2 Mil. Per Year
The Ochsner Clinic Foundation estimates that its budget for Lilly's sepsis agent Xigris could be over $2 mil. per year.
Ochsner Clinic Xigris Budget Projected At $2 Mil. Per Year
The Ochsner Clinic Foundation estimates that its budget for Lilly's sepsis agent Xigris could be over $2 mil. per year.
FDA Xigris Efficacy Analysis Suggests APACHE II Test Can Guide Therapy
An FDA analysis of Lilly's Xigris Phase III efficacy data suggests that the APACHE II sepsis scale may be a useful guide for identifying candidates for therapy.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: